SCI答復(fù)審稿人的回信技巧

/SCI答復(fù)審稿人的回信技巧一篇稿子從醞釀到成型歷經(jīng)艱辛，投出去之后又是漫長的等待，好容易收到編輯的回信，得到的往往又是審稿人不留情面的一頓狂批。這時(shí)候，如何有策略有技巧的回復(fù)審稿人就顯得尤為重要。好的回復(fù)是文章被接收的重要砝碼，而不恰當(dāng)?shù)幕貜?fù)輕則導(dǎo)致再次修改從而拖延發(fā)稿時(shí)間，重則導(dǎo)致文章被拒，前功盡棄。下面把我平時(shí)總結(jié)的一些答復(fù)審稿人的策略和寫回復(fù)信的格式和技巧跟大家交流一下。首先，絕對服從編輯的意見。在審稿人給出各自的意見之后，編輯一般不會再提出自己的意見。但是，編輯一旦提出某些意見，就意味著他認(rèn)為這是文章里的重大缺陷，至少是不合他的口味。這時(shí)，我們唯一能夠做的只能是服從。因?yàn)楫吘故侨思艺莆罩鷼⒂鑺Z的大權(quán)。第二，永遠(yuǎn)不要跟審稿人爭執(zhí)。跟審稿人起爭執(zhí)是非常不明智的一件事情。審稿人意見如果正確那就不用說了，直接照辦就是。如果不正確的話，也大可不必在回復(fù)中冷嘲熱諷，心平氣和的說明白就是了。大家都是青年人，血?dú)夥絼?，被人拍了?dāng)然不爽，被人錯(cuò)拍了就更不爽了。尤其是一些名門正派里的弟子，看到一審結(jié)果是major而不是minor本來就已經(jīng)很不爽了，難得抓住審稿人的尾巴，恨不得拖出來打死。有次審稿，一個(gè)審稿人給的意見是增加兩篇參考文獻(xiàn)（估計(jì)也就是審稿人自己的文章啦），結(jié)果作者在回復(fù)中寫到，makingareferenceisnotcharity！看到之后我當(dāng)時(shí)就笑噴了，可以想象審稿人得被噎成什么樣。正如大家所想的那樣，這篇稿子理所當(dāng)然的被拒了，雖然后來經(jīng)編輯調(diào)解改成了majorrevision，但畢竟耽誤的是作者自己的時(shí)間不是？第三，合理掌握修改和argue的分寸。所謂修改就是對文章內(nèi)容進(jìn)行的修改和補(bǔ)充，所謂argue就是在回復(fù)信中對審稿人的答復(fù)。這其中大有文章可做，中心思想就是容易改的照改，不容易改的或者不想改的跟審稿人argue。對于語法、拼寫錯(cuò)誤、某些詞匯的更換、對某些公式和圖表做進(jìn)一步解釋等相對容易做到的修改，一定要一毫不差的根據(jù)審稿意見照做。而對于新意不足、創(chuàng)新性不夠這類根本沒法改的，還有諸如跟算法A，B，C，D做比較，補(bǔ)充大量實(shí)驗(yàn)等短時(shí)間內(nèi)根本沒法完成的任務(wù)，我們則要有理有據(jù)的argue。在Argue的時(shí)候首先要肯定審稿人說的很對，他提出的方法也很好，但本文的重點(diǎn)是blablabla，跟他說的不是一回事。然后為了表示對審稿人的尊重，象征性的在文中加上一段這方面的discussion，這樣既照顧到了審稿人的面子，編輯那也能交待的過去。第四，聰明的掌握修改時(shí)間。拿到審稿意見，如果是minor，意見只有寥寥數(shù)行，那當(dāng)然會情不自禁的一蹴而就，一天甚至幾小時(shí)搞定修改稿。這時(shí)候，問題在于要不要馬上投回去了？我的意見是放一放，多看一看，兩個(gè)星期之后再投出去。這樣首先避免了由于大喜過望而沒能與時(shí)檢查出的小毛病，還不會讓編輯覺得你是在敷衍他。如果結(jié)果是major，建議至少放一個(gè)月再投出去，顯得比較鄭重。上面是一些一般性的答復(fù)審稿人的策略，在實(shí)際中的應(yīng)用還需要大家見仁見智。下面談?wù)劥饛?fù)信的寫法。寫答復(fù)信的唯一目的是讓編輯和審稿人一目了然的知道我們做了哪些修改。因此，所有的格式和寫法都要圍繞這一目的。一般來說可以把答復(fù)信分成三部分，即ListofActions,ResponsestoEditor,ResponsestoReviewers。第一部分ListofActions的作用是簡明扼要的列出所有修改的條目，讓編輯和審稿人在第一時(shí)間對修改量有個(gè)概念，同時(shí)它還充當(dāng)著修改目錄的作用，詳見下面的例子。剩下的兩部分是分別對編輯和審稿人所做的答復(fù)，格式可以一樣，按照“意見”－“argue”（如果有的話）－“修改”這樣逐條進(jìn)行。清楚醒目起見，可以用不同字體分別標(biāo)出，比如“意見”用italic，“argue”正常字體，“修改”用bold。下面舉例說明各部分的寫法和格式。編輯意見：請?jiān)谛薷母逯杏秒p倍行距。審稿人1：

意見1：置疑文章的創(chuàng)新性，提出相似的工作已經(jīng)被A和B做過。

意見2：算法表述不明確。

意見3：對圖3的圖例應(yīng)做出解釋。審稿人2：

意見1：圖2太小。

意見2：第3頁有個(gè)錯(cuò)別字。很顯然，根據(jù)上面的答復(fù)策略，我們準(zhǔn)備對除1號審稿人意見1之外的所有意見進(jìn)行相應(yīng)改動，而對1.1采取argue為主的策略。答復(fù)如下：ListofActionsLOA1:Therevisedmanuscriptisdoublespaced.

LOA2:AdiscussiononnoveltyofthisworkandacomparisonwithAandBhavebeenaddedinpage3.

LOA3:Aparagraphhasbeenaddedinpage5tofurtherexplainthealgorithm***.

LOA4:ExplanationsofthelegendofFigure3havebeenaddedinpage7.

LOA5:Figure2hasbeenenlarged.

LOA6:Alltyposhavebeenremoved.==================分頁=======================ResponsestoEditor請?jiān)谛薷母逯杏秒p倍行距。Wehavedoublespacedthetextthroughouttherevisedmanuscript,seeLOA1.==================分頁=======================ResponsestoReviewersToReviewer1:意見1：置疑文章的創(chuàng)新性，提出相似的工作已經(jīng)被A和B做過。Thankyouforpointingthisout.AandB’sresearchgroupshavedoneblablablabla.However,thefocusofourworkisonblablablabla,whichisverydifferentfromAandB’swork,andthisisalsothemajorcontributionofourwork.Wehaveaddedthefollowingdiscussiononthisissueinourrevisedmanuscript,seeLOA2.“blablablabla(此處把A和B的工作做一個(gè)review，并提出自己工作和他們的區(qū)別之處)”意見2：算法表述不明確。Wehaveaddedthefollowingdiscussiontofurtherexplainalgorithm***,seeLOA3.“blablablabla（此處進(jìn)一步解釋該算法）”意見3：對圖3的圖例應(yīng)做出解釋。WehaveaddedthefollowingexplanationsofthelegendofFigure3,seeLOA3.“blablablabla（圖3圖例的解釋）”==================分頁=======================ToReviewer2:意見1：圖2太小。WehaveenlargedFigure2,seeLOA4.意見2：第3頁有個(gè)錯(cuò)別字。Wehaveremovedalltypos,seeLOA5.==================分頁=======================總之，寫答復(fù)信的宗旨就是用最少的時(shí)間和工作量達(dá)到論文被接收的目的。這里權(quán)當(dāng)是拋磚引玉，希望和大家多多交流。

來源：pitlord999@小木蟲如何回復(fù)SCI投稿審稿人意見如何回復(fù)SCI投稿審稿人意見(1)

1.所有問題必須逐條回答。2.盡量滿足意見中需要補(bǔ)充的實(shí)驗(yàn)。3.滿足不了的也不要回避，說明不能做的合理理由。4.審稿人推薦的文獻(xiàn)一定要引用，并討論透徹。以下是本人對審稿人意見的回復(fù)一例，僅供參考。續(xù)兩點(diǎn)經(jīng)驗(yàn)：1，最重要的是逐條回答，即使你答不了，也要老實(shí)交代；不要太狡猾，以至于耽誤事；2，絕大部分實(shí)驗(yàn)是不要真追加的，除非你受到啟發(fā)，而想該投另外高檔雜志因?yàn)槟慵热灰呀?jīng)寫成文章，從邏輯上肯定是一個(gè)完整的“story”了。以上指國際雜志修稿。國內(nèi)雜志太多，以至于稿源吃緊，基本沒有退稿，所以你怎么修都是接受。我的文章水平都不高，主要是沒有明顯的創(chuàng)新性，也很苦惱。但是除了開始幾篇投在國內(nèi)雜志外，其他都在國際雜志（也都是SCI）發(fā)表。以我了解的情況，我單位其他同志給國內(nèi)雜志投稿，退稿的極少，只有一次被《某某科學(xué)進(jìn)展》拒絕。究其原因，除了我上面說的，另外可能是我單位寫稿子還是比較嚴(yán)肅，導(dǎo)師把關(guān)也比較嚴(yán)的緣故。自我感覺總結(jié)（不一定對）：1）國內(nèi)雜志審稿極慢（少數(shù)除外），但現(xiàn)在也有加快趨勢；2）國內(nèi)雜志編輯人員認(rèn)真負(fù)責(zé)的人不多，稿子寄去后，少則幾個(gè)月，多則一年多沒有任何消息；3）國內(nèi)雜志要求修改的稿子，如果你自己不修，他最后也給你發(fā)；4）國外雜志要求補(bǔ)充實(shí)驗(yàn)的，我均以解釋而過關(guān)，原因見少帖）。還因?yàn)椋汉苌匐s志編輯把你的修改稿再寄給當(dāng)初審稿人的，除非審稿人特別請求。編輯不一定懂你的東西，他只是看到你認(rèn)真修改，回答疑問了，也就接受了（當(dāng)然高檔雜志可能不是這樣，我的經(jīng)驗(yàn)只限定一般雜志（影響因子1-5）。歡迎大家批評指正。我常用的回復(fù)格式，呵呵。Dearreviewer:Iamverygratefultoyourcommentsforthemanuscript.Accordingwithyouradvice,weamendedtherelevantpartinmanuscript.Someofyourquestionswereansweredbelow.1）2）引用審稿人推薦的文獻(xiàn)的確是很重要的，要想辦法和自己的文章有機(jī)地結(jié)合起來。至于實(shí)驗(yàn)大部分都可以不用補(bǔ)做，關(guān)鍵是你要讓審稿人明白你的文章的重點(diǎn)是什么，這個(gè)實(shí)驗(yàn)對你要強(qiáng)調(diào)的重點(diǎn)內(nèi)容不是很必要，或者你現(xiàn)在所用的方法已經(jīng)可以達(dá)到目的就行了。最后要注意，審稿人也會犯錯(cuò)誤，不僅僅是筆誤也有專業(yè)知識上的錯(cuò)誤，因?yàn)榫庉嬚业膶徃迦宋幢厥悄氵@個(gè)領(lǐng)域的專家。只要自己是正確的就要堅(jiān)持。在回復(fù)中委婉地表達(dá)一下你的意見，不過要注意商討語氣哦！我得回復(fù)格式是這樣的：DearProfessorxx:Thankyouverymuchforyourletterdatedxxxxxxxxx,andthereferees’reports.Basedonyourcommentandrequest,wehavemadeextensivemodificationontheoriginalmanuscript.Here,weattachedrevisedmanuscript.intheformatsofbothPDFandMSword,foryourapproval.Adocumentansweringeveryquestionfromtherefereeswasalsosummarizedandenclosed.Arevisedmanuscript.withthecorrectionsectionsredmarkedwasattachedasthesupplementalmaterialandforeasycheck/editingpurpose.Shouldyouhaveanyquestions,pleasecontactuswithouthesitate.然后再附上Q/A，基本上囑條回答，寫的越多越好（老師語）。結(jié)果修改一次就接收了：）我的回復(fù)，請老外幫忙修改了DearEditor:Thankyouforyourkindletterof“”onNovember**,2005.Werevisedthemanuscript.inaccordancewiththereviewers’comments,andcarefullyproof-readthemanuscript.tominimizetypographical,grammatical,andbibliographicalerrors.Herebelowisourdescriptiononrevisionaccordingtothereviewers’comments.PartA(Reviewer1).Thereviewer’scomment:Theauthors’Answer:2.Thereviewer’scomment:Theauthors’Answer:

PartB(Reviewer2)1.Thereviewer’scomment:Theauthors’Answer:2.Thereviewer’scomment:Theauthors’Answer:Manygrammaticalortypographicalerrorshavebeenrevised.Allthelinesandpagesindicatedaboveareintherevisedmanuscript.Thankyouandallthereviewersforthekindadvice.Sincerelyyours,***

[精華]如何回復(fù)SCI投稿審稿人意見(2)

一個(gè)回復(fù)的例子(已接收)Majorcomments:1.TheauthorsneedtostrengthentheirresultsbyincludingMMPsecretion,andtran-matrigelmigrationbyapositivecontrolprogenitorcellpopulationi.e.enrichedhumanCD34cellsobtainedfrommobilizedPBL,sincethisisamoreclinicallyrelevantsourceofCD34cellswhichhasalsobeenshowntosecretebothMMP-9andMMP-2(ref.11).CD34enrichedcellsfromsteadystateperipheralbloodwhichalsosecreteMMPsarealsoofinterest.2.Infig1CpleasespecifywhichcelllinerepresentsMMP-negativecells.Thisneedstobeclarified,aswellasabetterexplanationofthemethodoftheprotocol.3.TheELISAresultsarerepresentedas"foldincrease"comparedtocontrol.Instead,wesuggestthatstandardsshouldbeusedandresultsshouldbepresentedasabsoluteconcentrationsandonlythencantheseresultsbecomparedtothoseofthezymography.4.Whendiscussingtheresults,theauthorsshoulddistinguishclearlybetweenspontaneousmigrationvschemotacticmigration.Furthermore,thehighspontaneousmigrationobtainedwithcordbloodCD34cellsshouldbecomparedtomobilizedPBLCD34enrichedcellsanddiscussed.5.TheauthorsclaimthattheclonogenicassaywasperformedtodeterminetheoptimumconcentrationforinhibitionofMMPactivitybyphenanthrolineandantiMMP-9mAb,howevertheyshouldclarifythatthisassaycanonlydeterminethetoxicityoftheinhibitorsandnottheiroptimalinhibitoryconcentrations.Minorcomments:1.Therearemanyspellingandsyntaxerrors,especiallyintheresultsanddiscussion,whichneedcorrection.a.Ofspecialimportance,isthepercentinhibitionofmigration,whichisdescribedaspercentofmigration.i.e.pg7:"MigrationofCBCD34wasreducedto73.3%?"Insteadshouldread"MigrationofCBCD34wasreducedby73.3%?"b.ThedegreesymbolneedstobeaddedtothenumbersinMaterialsandmethods.2.Itwouldbepreferabletocombinefigure1AandB,inordertoconfirmthereliabilityoffig.1Bbyapositivecontrol(HT1080).Answertoreferee1comment:1.MobilizedperipheralbloodisamoreclinicalsourceofCD34+cells,soitisnecessarytocomparetheMMP-9secretionandtrans-migrationabilityofCBCD34+cellswiththatofmobilizedPBCD34+cells.However,wecouldn'tobtainenoughmobilizedPBtoseparatePBCD34+cellsanddeterminetheMMP-9secretionandmigrationability,sowecouldn’tcomplementthestudyonPBCD34+cellsinthispaper.ResultsobtainedbyJanowska-WieczoreketalfoundthatmobilizedCD34+cellsinperipheralbloodexpressMMP-9.Furthermore,Domenech’sstudyshowedthatMMP-9secretionisinvolvedinG-CSFinducedHPCmobilization.Theirconclusionshavebeenaddedinthediscussion.Inourpresentstudy,ourcentralconclusionfromourdataisthatfreshlyisolatedCD34+stem/progenitorcellsobtainedfromCBproduceMMP-9.2.MMP-9negativecellusedinfig1CwasJurkatcell.Inzymographicanalysis,MMP-9wasnotdetectedinthemediumconditionedbyJurkatcell.ToexcludethatthecontaminatingcellsmayplayaroleintheobservedMMP-9production,wescreenedthemediaconditionedbydifferentproportionofCBmononuclearcellswithMMP-9negativecellsbyzymography.Thisresultmaybeconfusion.Actually,onlybydetectingthemediumconditionedby2X105CBmononuclearcells(MNC)/ml(sincethepuritiesofCD34+cellaremorethan90%),itcouldexcludetheMNCrole.Intherevisedmanuscript,weonlydetectedMMP-9activityandantigenlevelinthemediumconditionedby2X105CBmononuclearcells(MNC)/ml.ThereisnoMMP-9secretionbedetectedinthemediumconditionedby2X105CBMNC/ml.ItexcludedthepossibilitythattheMMP-9activityinCBCD34+cellsconditionedmediumisduetothecontaminationbyMNC.3.Inthisrevisedpaper,wehavedetectedtheMMP-9antigenlevelsbyusingcommercialspecificELISAkits(R&DSystem,sensitivity,0.156ng/ml).RecombinantMMP-9fromR&DSystemwasusedasastandard.Theresultsareexpressedintheabsoluteconcentration.Theabsoluteconcentrationresulthasbeenaddedinthepaper.AsshowninFig2,MMP-9levelsweredetectableinbothCBCD34+cellconditionedmediumandBMCD34+cellconditionedmedium.However,MMP-9levelwassignificantlyhigherinCBCD34+cellconditionedmediumthaninBMCD34+cellconditionedmedium(0.406±0.133ng/mlversus0.195±0.023ng/ml).AlthoughgelatinolyticactivitywasnotdetectedinmediaconditionedbyCD34+cellsfromBM,sensitivityofELISAfavorsthedetectionofMMP-9antigenintheBMCD34+.4.Inourstudy,toestablishthedirectlinkbetweenMMP-9andCBCD34+cellsmigration,weonlydeterminedtheroleofMMP-9inspontaneousmigrationofCBCD34+cells,butnotinchemotacticmigration.Actually,regulationofhematopoieticstemcellmigration,homingandanchorageofrepopulationcellstothebonemarrowinvolvesacomplexinterplaybetweenadhesionmolecules,chemokines,cytokinesandproteolyticenzymes.ResultsobtainedbythegroupsofVoermansrevealthatnotonlythespontaneousmigrationbutalsotheSDF-1inducedmigrationofCBCD34+cellsisgreatlyincreasedincomparisontoCD34+cellsfromBMandperipheralblood.5.CD34+cellsweobtainedineachcordbloodsamplewereverylimited.Itisnotenoughtoscreentheinhibitorsconcentrationstoselecttheoptimalinhibitoryconcentrations.Intheblockingexperiments,basedontheconcentrationsusedbyothersandthemanufacturer'srecommendation,wethendeterminedtheinhibitorsconcentrationsbyexcludingthetoxicityoftheinhibitorsinthatconcentration,whichwasdeterminedbyclonogenicassay.Minorcomments:1.Thespellingandsyntaxerrorshavebeencheckedandcorrected.2.Sincetheresultsinfigure1AandBwereobtainedfromtwoseparatedandparallelexperiments,itisnotfitnesstocombinetwofigures.這是我的一篇修稿回復(fù)，雜志是JBMR-A,影響因子3.652,已發(fā)表，供參考！ReplytothecommentsonJBMR-A-05-0172Comment:Reference#10ismissingfromtheIntroductionbutusedmuchlaterinthemanuscript.Shouldthesebeinorderusedinmanuscript?Reply:Themissingreferencehasbeenaddedintotherevisedmanuscript.Comment(continued):Whatisthesamplesizeforalltestsperformed?Reply:ThesamplesizefordrugreleaseandPCLdegradationtestswas3.0×3.0cm2,withathicknessofabout0.1mmandaweightofabout40mg.Thisdadahavebeenaddedintotherevisedmanuscript.Comment(continued):Figure7.ThereisnoscientificevidencepresentedintheTEMfiguretoconvincethisreviewerofsub-jets.ThisstatementonPage9cannotbemadewithoutclearevidenceduringthejetformation/separation.Figure7isjustalargefiberandsmallfiberfusedtogether,nootherconclusionthanthiscanbemade.Reply:Necessarychangeinthestatementshasbeenmadeintherevisedmanuscript.aswellasinthereferredfigureaccordingly.Comment(continued):Table3:Needstandarddeviationforallvaluesreportednotjustforaselectfew.EquationafterTable3notnecessary.Justreferencemethodused.Reply:Doneaccordingly.Comment(continued):Page11:"fasterweightloss"Whatwasthesamplesize?Whereisthestatisticalanalysisofthisdata?Thisreviewerdoesnotseeasignificantdifferenceinanyofthedatapresented,thusweightlosswouldbeconsideredequivalent.Reply:Althoughnottoomuchdifferencewasseen,theconclusionthat“theGS/PCLmembraneexhibitedarelativelyfasterweightlosscomparedwiththeRT/PCLmembrane”wasindeedapplicablethrough“one-wayanalysisofvariance(ANOVA)”analysis.Followingthereviewer’scomment,anewsub-sectionhasbeenaddedtothemanuscript.toaddressthestatisticalanalysisforthedata.Comment(continued):Page12:Whatisthesamplesizeforreleasedata?Lookslikeresultsbasedonasamplesizeofone?NeedstanddeviationsonthedatapresentedinFigure11.Whywasn'treleaseperformedandcomparedforallelectrospunconditionsinvestigatedotherwise?Reply:Threerepeatedtestswereperformedforeachsetofmeasurementsandtheresultingdatawereaveraged.Asstatedintherevisedmanuscript,eachsamplehadasquareareaof33cm2withaslightlydifferentthickness.StandarddeviationshavebeenaddedtothedatashowninFig.11.Thepresentmanuscript.aimedtoshowthatmedicaldrugscanbeencapsulatedinultrafinefibersthroughaco-axialelectrospinningprocess.Thedrugreleasedataintendedtoshowthattheencapsulationwassuccessful.Wedidnotconsideranyspecificapplicationinthispreliminarypaper,andinfactthetwodrugswerejustchosenasmodelillustration.Assuch,thereseemednotnecessarytoperform.releaseexperimentsforallofthemembraneselectrospunwithdifferentconditions(i.e.thecoreconcentrations)Comment(continued):Table3:Yang'sorYoung'sModulus(page10saysYoung's).Reply:Correctedaccordingly.Comment(continued):Figure11:Whatisthe%release,notjustconcentration.Whyjustthissmallsampleofreleasedata?Whereisthereleasedatafortheotherconditions?Reply:Unfortunately,wedidnotmeasuretheamountoftheshellmaterialinobtainingthecompositenanofibers.Namely,theflowrateoftheshellsolutionduringtheelectrospinningwasnotaccuratelycontrolledusinganinjectingpump.Hencethe%releasewasnotapplicable.PleaserefertothepreviousreplyrelatedtoPage12andFigure11fortheremainingcomments.Weacknowledgethereviewer’scommentsandsuggestionsverymuch,whicharevaluableinimprovingthequalityofourmanuscript.SCI生物醫(yī)學(xué)英文論文發(fā)表成功經(jīng)驗(yàn)發(fā)表成功經(jīng)驗(yàn)

SCI生物醫(yī)學(xué)英文論文發(fā)表成功經(jīng)驗(yàn)共享系列一（ClinicalChemistry）將自己近10年的科研工作中有關(guān)論文整理總結(jié)發(fā)表方面的一些信息貢獻(xiàn)出來，與大家共享！如有時(shí)間，我擬將一些已經(jīng)發(fā)表的文章，按照撰寫與發(fā)表的實(shí)際經(jīng)歷與過程，即通過案例分析每一個(gè)雜志的特色，審稿偏好，review意見與答復(fù)要點(diǎn)等逐一分析?？赡馨碾s志系列有：naturemethods，clinicalchemistry，analyticalchemistry，J.Clin.Immuno，Biomed.Microdev，F(xiàn)ront.Biosci，Mol.Cell.Biochem，J.Expert，Rev.Proteomics，Jbiochemistry等。本章先講解美國ClinicalChemistry雜志，一個(gè)臨床化學(xué)界的王牌雜志，近年其影響因子逐年攀升，現(xiàn)為7.7分。ClinicalChemistry由美國AACC每月出版，接受的文章包括與人體疾病相關(guān)的實(shí)驗(yàn)室研究，分析與分子診斷，儀器，資料處理，數(shù)據(jù)分析，臨床研究等投稿。ISSN：0009-9147網(wǎng)絡(luò)版ISSN：1530-8561【URL】【鏡像URL】【出版者】AmericanAssociationforClinicalChemistry(AACC)【收費(fèi)情況】免費(fèi),全文【內(nèi)容簡介】ClinicalChemistryisaninternationaljournaloflaboratorymedicineandmoleculardiagnostics.ClinicalChemistry--Thishighlyrespectedandoften-citedscientificjournalispublishedmonthlyandcontainspeer-reviewedmethodology,researchpapersandotherarticlesrelevanttoclinicalchemistryandrelatedlaboratorysciences.Itscirculationismorethan15,000.DavidE.Bruns,MD,Editor,(CharlottesvilleOffice)SandraWeaver,SeniorEditorialAssistantDonnaBrandl,EditorialAssistantShaneP.Cyr,EditorialAssistantMacFancher,Publisher,(WashingtonOffice)MiriamGonzalez,PublicationsCoordinator【目錄、摘要或全文上網(wǎng)等情況】FreeTOC,1965-FreeAbstract,1975-FreeFulltext,1997-1999Fulltext,1997-

【雜志被索引的情況】IndexedinChemicalAbstracts.【備注】ForfasteraccesstoClinicalChemistryOnlinefromthesecountriesusethisURL:,Brazil,China,France,Germany,HongKong,Ireland,Israel,Italy,Japan,Mexico,Russia,Singapore,SouthAfrica,SouthKorea,Spain,Sweden,Switzerland,Taiwan,TheNetherlands,UK該雜志是由美國臨床化學(xué)協(xié)會（AmericanAssociationforClinicalChemistry，AACC）主辦的，于1948年成立，總部位于華盛頓，擁有1萬余會員。先在網(wǎng)站注冊，登記，按照提示一步步提供文章名稱，摘要，作者姓名，所屬領(lǐng)域，關(guān)鍵詞，主文，圖表等等。轉(zhuǎn)換為PDF后就可以提交，然后給你一個(gè)查詢號，接著就是等待了。。。等了20多天，查閱狀態(tài)看到了第一次回信：HomeAuthorAreaReviewerAreaPersonalInfo.ClinChemHomeSignOutSubmitNewManuscript.InformationforAuthorsQueueSummaryFeedbackHelpFAQDecisionLetter[ReturntoQueue]To:作者姓名（電子郵件）From:Subject:ClinicalChemistry--Manuscript.DecisionCc:RE:ClinicalChemistryMSID#CLINCHEM/2002/036332TITLE:DearDr.xxx:Yourmanuscript.hasbeenexaminedbytwoexpertreviewers.Pleasevisit

toviewtheircomments.Forthereasonsdetailedinthesecomments,wecannotacceptthismanuscript.forpublicationinClinicalChemistryinthisform.Also,yourReference28isnotformattedproperly.OurInformationforAuthorswillofferassistancewithjournalstyle;itcanbefoundat

wouldconsiderarevisedversionthattakesthesecriticismsintoaccount.IfyoushouldresubmitthepaperIwouldalsoaskthatyouhaveseveralEnglishspeakingcolleaguesproofthepaperforgrammarandcomposition.Additionally,besuretoprovideadetailedpoint-by-pointresponsetothecommentsofthereviewers.Failuretodosowilldelayconsiderationoftherevisedmanuscript.Priortopublicationwerequirecopyrightreleasessignedbyallauthors.OurAuthorsAssurancesandAssignmentofCopyrightform.canbedownloadedfrom

.

Pleasenotethatallauthorsmustsignbothsectionsoftheform.(asignatureonthelowersectionmeansthatallconflictsofinteresthavebeendisclosedeveniftherearenone).Sendthecompletedform.tousbyFAX(434-979-7599).Sincerely,Dr.xxxnesleyAssociateEditorP.S.Youwillfindyourrevisedmanuscript.canbeuploadedinyour"SubmitaRevision"queueat

.

Pleasedonotbeginthesubmissionofyourrevisedmanuscript.untilyouarereadytosubmittheentiremanuscript.Achecklistregardingrequirementsforsubmissioncanbefoundat.

FiguresmustbeuploadedasImageFilesin.tifor.epsfilesat600DPI.Alternatively,youmayusePowerPointsoftwareforfiguresbutfontsmustbeembeddedandonlyoneimageperslide,oneslideperfile.Whenuploadingtherevisedversion,pleasebesuretoincludeinthe"ResponsetoReviews"fieldapoint-by-pointlistofallchangesmade,oryourrebuttal,inresponsetoeachofthereviewers?suggestions.P.P.S.Pleasenotethatifyourmanuscript.hascolorfigures,theauthorsareexpectedtobearthecostofprintingthem,exceptinthecaseofinvitedpapers.Thechargesforthesefiguresare$1500forthefirstcolorfigureorpartofafigure,and$500foreachadditionalcolorfigureorpartofafigure.Authorswillbebilledforcolorpublicationcostsunlesstheyrequestthattheirfiguresbeprintedinblackandwhite.該雜志一般為2個(gè)審稿人，審稿過程也較嚴(yán)格，都是本領(lǐng)域的大牛。后來我還有幸在一次會議上認(rèn)識到一個(gè)當(dāng)年的審稿人，但不知道是1還是2，呵呵！一般總是先鼓勵(lì)一段話，不寫了。。。下面問題就來了，共12個(gè)，有些很好回答，一句話就可以解釋清楚，有些就比較麻煩。還是舉例說明把1）實(shí)驗(yàn)的有效性和深度（atleastforafewsubstancesofmajorimportancedetectionlimits,cut-offvaluesandspecificityshouldhavebeenstudied.Alsothedescriptionoftheassayprincipleisnotquiteclear）沒辦法，只有一條路，補(bǔ)充相關(guān)實(shí)驗(yàn)，然后再投。2）語言問題（TheEnglishtextwouldhavetobesubstantiallyimproved）雖然這是一個(gè)美國雜志，但對語言的要求一點(diǎn)都不弱，投之前還是忽略了，沒辦法，慢慢修改。3）核心的技術(shù)問題（Acut-offvalueisgivenforMOLbutthedimensionismissing.Inthediscussionvariousanecdoticreportsaregivenforwhichnodataarepresentedunderresults.）重新驗(yàn)證討論。本來認(rèn)為很快就可以接受了，沒想到卻又等了一個(gè)半月（中間發(fā)過一次信件詢問）才收到回信。原來除了上次2個(gè)評委，這次又增加了一個(gè)獨(dú)立審稿人。。。原文如下：Yourrevisedmanuscript.hasbeenexaminedbytheoriginaltworeviewers,plusarecommendedthirdreviewerwithspecialexpertiseinthisarea.Pleasevisit

toretrievetheircomments.Thethreereviewersfindmeritinthework,buthavenumerousconstructivesuggestions（別害怕，其實(shí)就是幾個(gè)小問題）.Pleaseconsiderthesesuggestionscarefullyandprepareanimprovedversionthataddressestheseconcerns.Ihavealsonotedthatthereareseveralcolorfiguresincludedinthepaper,whichseemtobeusefulonlyincolor.Pleasebeawarethat(shouldyourpaperbeacceptedforpublication)authorsareexpectedtopaythecostsforpublicationofcolorfigures.Thechargeforthefirstcolorfigureis$1500;subsequentfigures,orpartsoffigures,are$500each.Ofcourse,ifyouwishtosubmitalternatefiguresinblackandwhite(orgrayscale),youmaydoso.Sincerely,Dr.xxxAssociateEditorP.S.Youwillfindyourrevisedmanuscript.canbeuploadedinyour"SubmitaRevision"queueat

.

Achecklistofrequirementsforsubmissioncanbefoundat

.

Whenuploadingtherevisedversion,pleasebesuretoincludeinthe"ResponsetoReviews"fieldapoint-by-pointlistofallchangesmade,oryourrebuttal,inresponsetoeachofthereviewersuggestions.Also,pleasesubmitcopyrightreleasesforallauthors.OurAuthor